LAMBERTUCCI, Catia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.007
EU - Europa 6.987
AS - Asia 5.293
SA - Sud America 711
AF - Africa 235
Continente sconosciuto - Info sul continente non disponibili 33
OC - Oceania 12
Totale 27.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.559
CN - Cina 2.135
SG - Singapore 1.633
RU - Federazione Russa 1.535
PL - Polonia 1.311
IT - Italia 1.186
DE - Germania 687
BR - Brasile 597
GB - Regno Unito 506
HK - Hong Kong 415
FR - Francia 404
UA - Ucraina 395
CA - Canada 375
VN - Vietnam 371
SE - Svezia 348
FI - Finlandia 257
KR - Corea 184
ZA - Sudafrica 166
TR - Turchia 148
IE - Irlanda 98
IN - India 88
JP - Giappone 87
MX - Messico 56
NL - Olanda 49
AR - Argentina 39
BE - Belgio 36
EU - Europa 33
BD - Bangladesh 32
ES - Italia 29
AT - Austria 25
CZ - Repubblica Ceca 25
EC - Ecuador 20
IQ - Iraq 19
IR - Iran 19
AE - Emirati Arabi Uniti 16
UZ - Uzbekistan 16
LT - Lituania 15
ID - Indonesia 14
KE - Kenya 14
PK - Pakistan 14
VE - Venezuela 13
CH - Svizzera 12
CO - Colombia 12
RO - Romania 12
TW - Taiwan 12
IL - Israele 11
PY - Paraguay 11
SA - Arabia Saudita 11
AU - Australia 9
AZ - Azerbaigian 9
DZ - Algeria 9
JO - Giordania 9
EG - Egitto 8
MA - Marocco 8
PH - Filippine 8
RS - Serbia 8
CL - Cile 7
PE - Perù 7
TN - Tunisia 7
AL - Albania 5
AM - Armenia 5
BG - Bulgaria 5
CI - Costa d'Avorio 5
DK - Danimarca 5
ET - Etiopia 5
GR - Grecia 5
LB - Libano 5
MY - Malesia 5
NP - Nepal 5
PA - Panama 4
TH - Thailandia 4
BO - Bolivia 3
EE - Estonia 3
HR - Croazia 3
HU - Ungheria 3
JM - Giamaica 3
KH - Cambogia 3
LV - Lettonia 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CM - Camerun 2
GE - Georgia 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
Totale 27.258
Salva come PNG Salva come JPEG
Città #
Fairfield 1.293
Ashburn 1.172
Warsaw 1.141
Woodbridge 1.112
Jacksonville 961
Singapore 810
Chandler 762
Houston 704
San Jose 686
Seattle 577
Wilmington 519
Ann Arbor 481
Cambridge 440
Boardman 417
Hong Kong 394
Beijing 347
Nanjing 318
Dallas 261
Toronto 242
Camerino 222
The Dalles 203
Council Bluffs 193
Los Angeles 191
New York 156
Seoul 156
Kraków 152
Johannesburg 151
Columbus 143
San Mateo 143
Tongling 140
Dearborn 137
Lawrence 133
Princeton 133
Helsinki 129
Istanbul 121
Ho Chi Minh City 115
Lauterbourg 113
Düsseldorf 108
Ogden 108
Moscow 106
Nanchang 102
Dublin 97
London 96
Buffalo 93
Hanoi 88
Shanghai 85
Lachine 83
Santa Clara 81
Chicago 73
Guangzhou 69
São Paulo 69
Frankfurt am Main 67
Tokyo 67
Shenyang 66
San Diego 63
Kunming 62
Milan 61
Munich 59
Tianjin 58
Edinburgh 44
St Louis 44
Jiaxing 43
Hebei 42
Orem 42
Centro 39
Rome 38
Brussels 35
Atlanta 31
Changsha 30
Ningbo 30
Jinan 28
Manchester 28
Stockholm 28
Denver 27
Phoenix 27
Chennai 26
Trieste 26
Hangzhou 25
Mexico City 25
Wuhan 25
Montreal 24
Poplar 24
Verona 24
Ascoli Piceno 23
Brooklyn 23
Dong Ket 23
San Francisco 23
Hefei 22
Norwalk 22
Boston 21
Falls Church 20
Orange 20
Philadelphia 20
Turku 20
Bremen 19
Jinhua 19
Redwood City 19
Salt Lake City 19
Rio de Janeiro 18
Tampa 18
Totale 18.233
Salva come PNG Salva come JPEG
Nome #
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 450
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 403
Overview on Radiolabel-Free in Vitro Assays for GPCRs 399
Pharmacological characterization of the GPR17 receptor dual profile 393
GPR17 receptor modulators and their therapeutic implications: review of recent patents 389
The G Protein-Coupled Receptor GPR17: Overview and Update 370
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 363
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 355
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 325
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 297
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 293
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 282
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 274
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 264
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 264
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 262
Biomarkers Mapping in a Neuropathic Pain Mice Model with Sciatic Nerve Chronic Constriction Injury (CCI). 256
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 250
A taxane epoxide from taxus wallichiana 248
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 248
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 247
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 247
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 244
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 243
Human cytidine deaminase: understanding the catalytic mechanism 239
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 239
Synthesis and evaluation of hexitol nucleoside congeners as ambiguous nucleosides 237
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 236
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 234
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 234
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 233
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 233
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 232
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 231
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 230
New sensible method to quantize the intestinal absorption of receptor ligands 224
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 223
Adenosine deaminase: Functional implications and different classes of inhibitors 223
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 220
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 217
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 217
Antiviral properties of deazaadenine nucleoside derivatives 214
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 213
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 210
Synthesis of a conformationally restricted analogue of paclitaxel 210
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 210
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 208
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 207
Synthesis and NMR-Driven Conformational Analysis of Taxol Analogues Conformationally Constrained on the C13 Side Chain 206
2- And 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosines receptors 206
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 205
2-phenylhydroxypropynyladenosine derivatives as high potent agonists at A(2B) adenosine receptor subtype 204
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 204
Adenosine receptor modeling: what does the A2A crystal structure tell us? 204
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 204
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 203
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 202
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 202
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 198
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 198
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 198
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 196
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 196
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 195
The Chemistry and Occurrence of Taxane Derivatives. XXVI. A Reactivity Study on 11(15→1)Abeotaxanes 193
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 193
Solid phase synthesis and antiprotozoal evaluation of di- and trisubstituted 5 '-carboxamidoadenosine analogues 191
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 189
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 189
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 188
[3H]HEMADO – a novel tritiated agonist selective for the human adenosine A(3) receptor 186
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 185
A(2B) adenosine receptor agonists: synthesis and biological evaluation of 2-phenylhydroxypropynyladenosine and NECA derivatives 183
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. 183
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 183
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 183
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 177
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 177
Coupling of 2,6-disubstituted purines to ribose-modified sugars 176
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands 176
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 176
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 176
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 176
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 175
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 174
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 171
Probing ambiguous base-pairs by genetic transformation with XNA templates 167
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 166
A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders 166
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 162
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 161
Adenosine receptor agonists:synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives 160
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 155
Synthesis of new nucleosides by coupling of chloropurines with 2- and 3-deoxy derivatives of N-methyl-D-ribofuranuronamide 155
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 153
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 152
Substituted adenine derivatives as novel P2X3 receptor ligands 149
Totale 22.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.144
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.144
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021256 0 0 0 0 0 0 0 0 0 0 0 256
2021/20221.648 185 417 34 40 77 81 94 127 125 176 114 178
2022/20231.815 203 122 46 308 177 259 9 106 316 105 111 53
2023/20241.412 190 79 95 63 66 127 55 91 163 38 42 403
2024/20254.798 191 112 389 227 181 291 574 1.190 391 295 307 650
2025/20266.698 426 374 693 956 775 514 1.105 496 410 458 373 118
Totale 27.686